Commentary · 31 Oct 2024
Conference abstract
Antibacterials: Past, Present ? and Future?
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
T he last novel antibacterial class to win approval was discovered over 25 years ago. During the next decade, genomics, high-throughput screening and combinatorial chemistry dominated antibacterial drug di scovery with little success. Th is, coupled with the intrinsic low return on investment of antibacterials, led most pharmaceutical companies to abandon the fi eld out-licensing the few compounds still in development to small biotechnology companies. At the same time, the ready availability of antibacterials for human and animal health worldwide led to alarming levels of resistance in both gram-positive and gram-negative bacteria. Th e situation is certain to deteriorate in the coming years and has brought a sense of urgency to the discovery of new/improved antibacterials. Th e success of daptomycin, tigecycline and linezolid ? and the resurgence of polymyxin ? despite toxicity liabilities underscore the commercial viability of antibacterials. One approach likely to s ucceed is targeting bacterial enzymes using insights and compounds acquired from other therapeutic ar eas. Another approach is using PK/PD (or manipulating them via formulations) to reduce the toxicity of eff ective but toxic antibacterials to acceptable levels for their re-introduction in the clinic
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 21 Mar 2022
Herbal drugs : past, present and future scenario in India
Conference abstract · 31 Jul 2021
Antimicrobial Resistance, Past, Present, and Future Prospects
Conference abstract · 2021
Generating real world evidence for regulators: the past, the present and the future
Short communication · 31 Aug 2020
Story of Gum Arabic (Acacia senegal), past, present and future
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Article · 5 Oct 2026
Long COVID in pediatric and young adult patients: a review of evaluation for microvascular changes, endothelial dysfunction, and arterial stiffness
Article · 12 Jun 2026
Advances in Bioavailability Through Innovative Drug Delivery Systems and Formulation Technologies
Article · 12 Jun 2026
Bioequivalence Study Design and Methodological Approaches in Generic Drug Evaluation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Nafsika H. Georgopapadakou”
